[go: up one dir, main page]

PE20090875A1 - Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos - Google Patents

Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos

Info

Publication number
PE20090875A1
PE20090875A1 PE2008001783A PE2008001783A PE20090875A1 PE 20090875 A1 PE20090875 A1 PE 20090875A1 PE 2008001783 A PE2008001783 A PE 2008001783A PE 2008001783 A PE2008001783 A PE 2008001783A PE 20090875 A1 PE20090875 A1 PE 20090875A1
Authority
PE
Peru
Prior art keywords
modulators
methyl
metabotropic glutamate
glutamate receptors
tetrazol
Prior art date
Application number
PE2008001783A
Other languages
English (en)
Inventor
Erwan Arzel
Louise Edwards
Methvin Isaac
Donald A Mcleod
Abdelmalik Slassi
Tao Xin
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567640&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090875(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090875A1 publication Critical patent/PE20090875A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE TETRAZOL DE FORMULA (I) DONDE R1 ES PIRIDINA, PIRIMIDINA, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-(4-METIL-5-{(1R)-1-[2-(3-METILFENIL)-2H-TETRAZOL-5-IL]ETOXI}-4H-1,2,4-TRIAZOL-3-IL)PIRIMIDINA, 5-(4-METIL-5-{(1R)-1-[2-(3-METILFENIL)-2H-TETRAZOL-5-IL]ETOXI}-4H-1,2,4-TRIAZOL-3-IL)PIRIMIDINA, 2-METIL-5-(4-METIL-5-{(1R)-1-[2-(3-METILFENIL)-2H-TETRAZOL-5-IL]ETOXI}-4H-1,2,4-TRIAZOL-3-IL)PIRAZINA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON MODULADORES DE LOS RECEPTORES DE GLUTAMATO METABOTROPICOS (mGluR5) SIENDO UTILES EN EL TRATAMIENTO DE REFLUJO GASTROESOFAGICO, DISPEPSIA FUNCIONAL, ENFERMEDAD DE PARKINSON, SINDROME DE DOWN
PE2008001783A 2007-10-19 2008-10-17 Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos PE20090875A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98129407P 2007-10-19 2007-10-19

Publications (1)

Publication Number Publication Date
PE20090875A1 true PE20090875A1 (es) 2009-08-08

Family

ID=40567640

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001783A PE20090875A1 (es) 2007-10-19 2008-10-17 Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos

Country Status (21)

Country Link
US (1) US7960422B2 (es)
EP (1) EP2231647A4 (es)
JP (1) JP2011500673A (es)
KR (1) KR20100090777A (es)
CN (1) CN101896480A (es)
AR (1) AR068921A1 (es)
AU (1) AU2008312055A1 (es)
BR (1) BRPI0818448A2 (es)
CA (1) CA2703425A1 (es)
CL (1) CL2008003085A1 (es)
CO (1) CO6321281A2 (es)
CR (1) CR11376A (es)
DO (1) DOP2010000119A (es)
EA (1) EA201000654A1 (es)
IL (1) IL204958A0 (es)
MX (1) MX2010004272A (es)
PE (1) PE20090875A1 (es)
TW (1) TW200934771A (es)
UY (1) UY31403A1 (es)
WO (1) WO2009051556A1 (es)
ZA (1) ZA201002694B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1847543A1 (de) 2006-04-19 2007-10-24 Boehringer Ingelheim Pharma GmbH & Co. KG Dihydrothienopyrimidine zur Behandlung von entzündlichen Erkrankungen
KR20100075930A (ko) 2007-10-19 2010-07-05 베링거 인겔하임 인터내셔날 게엠베하 헤테로사이클-치환된 피페라지노-디하이드로티에노피리미딘
RS52271B (sr) 2007-10-19 2012-10-31 Boehringer Ingelheim International Gmbh Substituisani piperidino-dihidrotienopirimidin
US8486948B2 (en) 2007-10-19 2013-07-16 Boehringer Ingelheim International Gmbh Piperazinodihydrothienopyrimidine derivatives
WO2010033977A2 (en) 2008-09-22 2010-03-25 Cayman Chemical Company Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CN102256967A (zh) * 2008-12-18 2011-11-23 阿斯利康(瑞典)有限公司 制备3-{4-甲基-5-[(1r)-1-(2-(3-甲基苯基-2h-四唑-5-基)-乙氧基]-4h-[1,2,4]三唑-3-基}-吡啶、4-甲基-3-甲基硫基-5-(吡啶-3-基)-1,2,4-三唑和(1r)-1-[2-(3-甲基苯基)-2h-四唑-5-基]乙醇的方法
CN102725281A (zh) * 2009-06-05 2012-10-10 奥斯陆大学医院公司 作为wtn通路抑制剂的氮杂茂类衍生物
US9096587B2 (en) 2010-12-08 2015-08-04 Oslo University Hospital Hf Triazole derivatives as Wnt signaling pathway inhibitors
CA2830458A1 (en) 2011-03-18 2012-09-27 Novartis Ag Combinations of alpha 7 nicotinic acetylcholine receptor activators and mglur5 antagonists for use in dopamine induced dyskinesia in parkinson's disease
US20130059866A1 (en) 2011-08-24 2013-03-07 Boehringer Ingelheim International Gmbh Novel piperidino-dihydrothienopyrimidine sulfoxides and their use for treating copd and asthma
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
CN106032377A (zh) * 2015-03-12 2016-10-19 天津药物研究院有限公司 四氮唑类urat1抑制剂、制备方法及其在高尿酸血症和痛风治疗上的用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663332A (en) 1985-10-10 1987-05-05 Hoffman-La Roche Inc. 5-substituted N-alkylated tetrazoles
US5492919A (en) 1991-08-03 1996-02-20 Smithkline Beecham P.L.C. 5-HT4 receptor antagonists
DE10023430A1 (de) 2000-05-12 2001-11-15 Bayer Ag Substituierte N-Benzoyl-N'-(tetrazolylphenyl)-harnstoffe
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0121033D0 (en) 2001-08-30 2001-10-24 Novartis Ag Organic compounds
DE60226756D1 (de) 2001-10-04 2008-07-03 Merck & Co Inc Heteroarylsubstituierte tetrazolmodulatoren des metabotropischen glutamatrezeptors-5
CA2478799C (en) 2002-03-12 2009-12-29 Merck & Co., Inc. Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
MXPA05001594A (es) * 2002-08-09 2005-09-20 Astrazeneca Ab 1,2,4" oxadiazoles como moduladores de receptor-5 metabotropico de glutamato.
WO2005077345A1 (en) * 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
US7585881B2 (en) * 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US20070185100A1 (en) 2004-02-18 2007-08-09 Astrazeneca Ab Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
KR20070027503A (ko) * 2004-02-18 2007-03-09 아스트라제네카 아베 트리아졸 화합물 및 대사성 글루타메이트 수용체길항제로서 이들의 용도
CN1918137B (zh) * 2004-02-18 2012-08-01 阿斯利康(瑞典)有限公司 四唑化合物及其作为代谢型谷氨酸受体拮抗剂的应用
UY29796A1 (es) * 2005-09-29 2007-04-30 Astrazeneca Ab Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor
TW200811156A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators IV
TW200811157A (en) 2006-05-05 2008-03-01 Astrazeneca Ab mGluR5 modulators I

Also Published As

Publication number Publication date
DOP2010000119A (es) 2010-05-31
AU2008312055A1 (en) 2009-04-23
BRPI0818448A2 (pt) 2015-05-12
WO2009051556A1 (en) 2009-04-23
US20090131454A1 (en) 2009-05-21
TW200934771A (en) 2009-08-16
CA2703425A1 (en) 2009-04-23
AR068921A1 (es) 2009-12-16
EA201000654A1 (ru) 2010-12-30
CR11376A (es) 2010-07-19
JP2011500673A (ja) 2011-01-06
EP2231647A1 (en) 2010-09-29
ZA201002694B (en) 2011-03-30
US7960422B2 (en) 2011-06-14
MX2010004272A (es) 2010-04-30
IL204958A0 (en) 2010-11-30
CL2008003085A1 (es) 2009-10-09
UY31403A1 (es) 2009-05-29
CO6321281A2 (es) 2011-09-20
CN101896480A (zh) 2010-11-24
KR20100090777A (ko) 2010-08-17
EP2231647A4 (en) 2011-08-31

Similar Documents

Publication Publication Date Title
PE20090875A1 (es) Derivados de tetrazol como moduladores de los receptores de glutamato metabotropicos
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20120812A1 (es) Compuestos vinil indazolilo
PE20090328A1 (es) Derivados de oxadiazol como moduladores de los receptores metabotropicos de glutamato
PE20091042A1 (es) Ligandos de oxadiazol del receptor metabotropico del glutamato y su uso como potenciadores - 841
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20051173A1 (es) Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3
PE20081884A1 (es) Inhibidores heterociclicos de la aspartil proteasa
PE20081532A1 (es) Compuestos novedosos
PE20141529A1 (es) Derivados de biciclo [3,2,1] octilamida y sus usos
TW200637550A (en) Thiazole-4-carboxamide derivatives as mGluR5 antagonists
PE20090312A1 (es) DERIVADO DE 17 -CIANO-18a-HOMO-19-NOR-ANDROST-4-ENO
PE20091035A1 (es) Derivados de 2-aminopirimidina
EA200970326A1 (ru) Алкильные производные в качестве метаботропных рецепторов глутамата
PE20110341A1 (es) COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20081659A1 (es) Agonistas de gpcr
PE20080858A1 (es) Compuestos de n-aril pirazol y composiciones que los contienen
PE20130227A1 (es) Formulaciones farmaceuticas que comprenden derivados de 1-(beta-d-glucopiranosil)-2-tienilmetilbenceno como inhibidores de sglt
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
IL189191A0 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
PE20091057A1 (es) Antagonistas del receptor mineralcorticoide y metodos de uso
PE20060079A1 (es) DERIVADOS DE PIRIDILO COMO ANTAGONISTAS DEL RECEPTOR mGlus5
PE20060937A1 (es) Derivados de sulfonilbencimidazol como agonistas del receptor cannabinoide 2 (cb2)
PE20090487A1 (es) Compuestos heterociclos como inhibidores de lta4h

Legal Events

Date Code Title Description
FD Application declared void or lapsed